Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders From: Archives of Pathology & Laboratory Medicine | Date: November 1, 2002| Author: Bauer, Kenneth A; Heit, John A; Kujovich, Jody L; Press, Richard D | Copyright College of American Pathologists Nov 2002. Provided by ProQuest LLC.Copyright information

* Objective.-To review the current state of the art regarding the role of the clinical laboratory in diagnostic testing for the factor V Leiden (FVL) thrombophilic mutation (and other protein C resistance disorders), and to generate, through literature reviews and opinions of recognized thought-leaders, expert consensus recommendations on methodology and diagnostic, prognostic, and management issues pertaining to clinical FVL testing.

Data Sources, Extraction, and Synthesis.-An initia...

Related newspaper, magazine, and journal articles from HighBeam Research

	Activated protein C resistence, the factor V leiden mutation, and a laboratory testing algorithm Archives of Pathology & Laboratory Medicine ; * Objectives.-To present the current understanding of factor V Leiden and activated protein C resistance, and to propose a laboratory testing algorithm. Data Sources.-Publications on MEDLINE with the terms factor V Leiden or activated protein C resistance through mid 2001, as well as publications
	Testing for resistance to activated protein C factor V R506Q / In reply Archives of Pathology & Laboratory Medicine ; To the Editor.-In their article, Montes et al1 reported that the cost per test for materials to perform functional screening for activated protein C resistance (APC-R) was less than 20% of the cost for materials to perform "confirmatory" molecular biologic test. The costs cited by these authors are
	Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients Archives of Pathology & Laboratory Medicine ; * Objective.-To compare functional and molecular biological tests for resistance to activated protein C (APC)/ factor V R506Q, the most common cause of familial thrombosis. Methods.-We developed functional and molecular biological tests for resistance to APC/factor V R506Q at our institution and
	Functional activated protein C resistance assays: Correlation with factor V DNA analysis is better with RVVT-than APTT-based assays British Journal of Biomedical Science ; Abstract: We compare results of factor V DNA analysis with three different clotting-based assays designed to detect activated protein C (APC) resistance (APCR), using samples from 958 patients undergoing assessment for thrombophilia. The original and most commonly used APTT-based procedure
	Activated Protein C Resistance and Factor V Leiden: A Review Archives of Pathology & Laboratory Medicine ; Context.-Factor V Leiden (FVL) is the most common heritable cause of venous thrombosis. It is caused by a single nucleotide substitution resulting in an R506Q mis-sense mutation, resulting in factor V resistance to activated protein C (APC) inactivation. Carriers of FVL have an increased
	Bilateral thalamic infarction in a patient with factor V Leiden mutations Mayo Clinic Proceedings ; Resistance to activated protein C (APC), typically due to a factor V Leiden mutation, is the most common cause of sporadic venous thrombosis in the general population.1 The reported incidence of APC resistance due to this mutation is between 2% and 7%.2 Despite the role of APC resistance in venous
	Activated Protein C for the Treatment of Fulminant Meningococcal Septicaemia Anaesthesia and Intensive Care ; SUMMARY We report two cases of meningococcal septic shock with multiple organ failure treated with prompt administration of activated protein C. This was associated with a rapid clinical improvement and early cessation of organ support. Both patients survived to hospital discharge with no long-term
	Factor V Leiden: association with venous thromboembolism in pregnancy and screening issues British Journal of Biomedical Science ; ABSTRACT Disturbances of the natural balance between procoagulant and anticoagulant mechanisms can result in bleeding or thrombotic tendencies. Factor V, on activation by thrombin to factor Va, forms an essential component of the prothrombinase complex, in which it demonstrates its cofactor
	Scientists find gene for clotting disorder. (action of activated protein C blocked in people with family history of venous thrombosis) (Brief Article) Science News ; People with venous thrombosis suffer from blood that forms clots aggressively. This week, Dutch researchers report finding a mutant gene that underlies this clotting disorder. Researchers had long known that venous thrombosis runs in families. In people with the condition, blood pools in the veins
	Activated protein C resistance assay performance: Improvement by sample dilution with factor V-deficient plasma Archives of Pathology & Laboratory Medicine ; Objectives.-To evaluate a modification of a commercially available reagent kit (COATEST APC Resistance Kit) for functional activated protein C (APC) resistance testing, and to determine the ability of the modified assay to demonstrate APC resistance in patients receiving warfarin.

See all results.